Get the Stockscreener App
26.50
5.09%
-1.42
After Hours:
26.50
Phibro Animal Health Corp stock is traded at $26.50, with a volume of 240.94K.
It is down -5.09% in the last 24 hours and up +3.76% over the past month.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
See More
Previous Close:
$27.92
Open:
$27.6
24h Volume:
240.94K
Relative Volume:
0.87
Market Cap:
$539.74M
Revenue:
$982.01M
Net Income/Loss:
$14.80M
P/E Ratio:
71.62
EPS:
0.37
Net Cash Flow:
$37.02M
1W Performance:
-9.99%
1M Performance:
+3.76%
6M Performance:
+21.50%
1Y Performance:
+40.36%
1-Day Range:
$26.39
$27.80
1-Week Range:
$26.39
$29.80
52-Week Range:
$16.16
$31.80
Phibro Animal Health Corp Stock (PAHC) Company Profile
Name
Phibro Animal Health Corp
Sector
Phone
201-329-7300
Address
GLENPOINTE CENTRE EAST, 3RD FLOOR, TEANECK, NJ
Compare PAHC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PAHC
Phibro Animal Health Corp
|
26.50 | 1.13B | 982.01M | 14.80M | 37.02M | 0.37 |
|
ZTS
Zoetis Inc
|
145.79 | 66.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 42.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.43 | 43.30B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.45 | 19.30B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
128.23 | 13.53B | 2.41B | 305.80M | 492.20M | 2.95 |
Phibro Animal Health Corp Stock (PAHC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-16-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-10-24 | Initiated | JP Morgan | Neutral |
| Dec-07-23 | Initiated | Exane BNP Paribas | Underperform |
| Dec-21-22 | Initiated | ROTH Capital | Buy |
| Jul-25-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-10-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Nov-18-21 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Jul-07-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Aug-06-20 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Feb-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Jan-28-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Sep-05-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Aug-29-19 | Reiterated | BofA/Merrill | Underperform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| May-23-19 | Initiated | Guggenheim | Neutral |
| May-09-19 | Upgrade | Gabelli & Co | Hold → Buy |
| Aug-23-17 | Resumed | BofA/Merrill | Underperform |
| Jun-02-17 | Downgrade | Credit Suisse | Outperform → Neutral |
| Dec-15-16 | Initiated | Piper Jaffray | Overweight |
| Nov-11-16 | Downgrade | Macquarie | Neutral → Underperform |
| Nov-10-16 | Downgrade | Gabelli & Co | Buy → Hold |
| Apr-11-16 | Reiterated | Guggenheim | Buy |
| Feb-04-16 | Initiated | Credit Suisse | Outperform |
| Jan-15-16 | Downgrade | Barclays | Overweight → Underweight |
| Sep-30-15 | Initiated | Gabelli & Co | Buy |
| Apr-24-15 | Reiterated | Barclays | Overweight |
| Apr-21-15 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-06-14 | Initiated | Barclays | Overweight |
View All
Phibro Animal Health Corp Stock (PAHC) Latest News
What analysts say about Phibro Animal Health Corporation stock outlookOversold Opportunity Scanner with RSI Data - Newser
Trend analysis for Phibro Animal Health Corporation this weekWealth Accumulation Outlook for Safe Investors - Newser
Why Phibro Animal Health Corporation stock attracts strong analyst attentionFree High Return Stock Focus With Safety - Newser
Animal Feed Minerals Market Size and Share Forecast Outlook 2025 - openPR.com
What to do if you’re stuck in Phibro Animal Health CorporationSwing Trade Picks with High Potential - Newser
How to build a custom watchlist for Phibro Animal Health CorporationPredictive AI Signals for Short-Term Trading - Newser
Published on: 2025-07-30 19:00:17 - metal.it
Competitive Positioning of Phibro Animal Health Corporation: Is It Leading or LaggingFree Weekly Setup With 3x Return Potential - Newser
Phibro Animal Health Corporation Declares Quarterly Dividend - FinancialContent
How did FITBO's Q1 2024 earnings surprise impact short-term trading? - AInvest
Animal Growth Promoter Market Outlook 2025 to 2035: Growth - openPR.com
What are analysts’ price targets for Phibro Animal Health Corporation in the next 12 monthsHigh-profit stock alerts - jammulinksnews.com
Will Phibro Animal Health Corporation benefit from macro trendsFree Alpha Driven Watchlist With Alerts - Newser
Will Phibro Animal Health Corporation Stock Benefit from AI and Green Energy Trends200 Percent Profit Outlook - Newser
Phibro Animal Health Corporation (NASDAQ:PAHC) Shares Sold by Bank of New York Mellon Corp - Defense World
What analysts say about Phibro Animal Health Corporation stockConsistently high yield - jammulinksnews.com
Why Phibro Animal Health (PAHC) is a Top Value Stock for the Long-Term - Yahoo Finance
Phibro Animal Health Corporation Stock Analysis and ForecastConsistent triple returns - PrintWeekIndia
Principal Financial Group Inc. Has $2.17 Million Holdings in Phibro Animal Health Corporation (NASDAQ:PAHC) - Defense World
Phibro Animal Health Corporation (NASDAQ:PAHC) Stock Holdings Trimmed by Teacher Retirement System of Texas - Defense World
Elevance Health Q2 Earnings Miss Estimates on Rising Medical Costs - TradingView
Should Value Investors Buy Phibro Animal Health (PAHC) Stock? - Yahoo Finance
Best Growth Stocks to Buy for July 17th - The Globe and Mail
3 Reasons Why Growth Investors Shouldn't Overlook Phibro (PAHC) - Yahoo Finance
How Phibro Animal Health Corporation stock performs during market volatilityFree Stock Index Interpretation - Newser
Best Growth Stocks to Buy for July 15th - The Globe and Mail
Here's Why Phibro Animal Health (PAHC) is a Strong Momentum Stock - Yahoo Finance
Phibro Animal Health (PAHC) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Phibro Animal Health stock reaches 52-week high at $30.60 By Investing.com - Investing.com South Africa
Phibro Animal Health stock reaches 52-week high at $30.60 - Investing.com India
Phibro (PAHC) Soars 6.8%: Is Further Upside Left in the Stock? - Yahoo Finance
Phibro Animal Health (NASDAQ:PAHC) Upgraded by JPMorgan Chase & Co. to Overweight Rating - Defense World
Phibro's Feed Play Pays Off: JPMorgan Upgrades On Zoetis Deal Boost - Benzinga
Phibro Animal Health (PAHC) Rises on J.P. Morgan Upgrade - GuruFocus
Phibro Animal Health shares surge on J.P. Morgan upgrade - grafa.com
Phibro Animal Health stock surges after JPMorgan upgrade to Overweight By Investing.com - Investing.com Nigeria
Phibro Animal Health stock surges after JPMorgan upgrade to Overweight - Investing.com Australia
Phibro rises after J.P. Morgan upgrades to 'overweight' - TradingView
U.S. Bancorp To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday - NewsBreak: Local News & Alerts
Phibro Animal Health (PAHC) Receives Upgrade and Price Target Bo - GuruFocus
Phibro Animal Health Corp Stock (PAHC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):